Feature|Articles|May 14, 2024
- Pharmaceutical Executive: May 2024
- Volume 44
- Issue 5
Pharmaceutical Executive: May 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive May 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 2 years ago
'Patients are Waiting'about 2 years ago
Today’s New Messaging Mix: The State of Pharma Marketing in 2024about 2 years ago
Patient Treatment & Travel: The Need for Stepped-Up Supportabout 2 years ago
A Biosimilars Roadmap: Understanding Payer Perceptionsabout 2 years ago
Avoiding the Digital Age is Hurting Research Effortsover 2 years ago
Biotech’s Road to Recovery Takes a Wobbly Turnover 2 years ago
Yvonne Greenstreet: Answering the CallAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Significance of FDA’s First Warning Letter for Inappropriate Use of AI
2
Jazz Pharmaceuticals to Acquire Actio Biosciences for $1.32 Billion
3
Generating Commercial Evidence from Agentic Field and Brand Engagement to Accelerate Launch Performance
4
FDA Grants Accelerated Approval to Tudriqev in Combination with Nivoumab for Advanced Melanoma
5